SAN DIEGO, JANUARY 20, 2012
LA JOLLA PHARMACEUTICAL COMPANY ACQUIRES GCS-100, A FIRST-IN-CLASS GALECTIN-3 ANATAGONIST

SAN DIEGO, APRIL 13, 2011
LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES REVERSE STOCK SPLIT

SAN DIEGO, APRIL 5, 2011
LA JOLLA PHARMACEUTICAL COMPANY TO FOCUS ON REGENERATIVE MEDICINE WITH THE ACQUISITION OF NOVEL CLASS OF COMPOUNDS

SAN DIEGO, DECEMBER 7, 2010
LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES APPOINTMENT OF DR. BERTRAND C. LIANG TO BOARD OF DIRECTORS

SAN DIEGO, SEPTEMBER 7, 2010
LA JOLLA PHARMACEUTICAL COMPANY PROVIDES UPDATE ON SEARCH FOR CLINICAL PRODUCTS TO IN-LICENSE OR ACQUIRE

SAN DIEGO, MAY 25, 2010
LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES FINANCING OF UP TO $16.3 MILLION

SAN DIEGO, MARCH 5, 2010
LA JOLLA PHARMACEUTICAL ANNOUNCES TERMINATION OF MERGER AGREEMENT WITH ADAMIS PHARMACEUTICALS

SAN DIEGO, MARCH 3, 2010
LA JOLLA PHARMACEUTICAL ANNOUNCES DELISTING FROM NASDAQ AND FAILURE TO GET STOCKHOLER VOTE FOR MERGER